Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- BMC medicine
- Publicado em
- 19 set 2024
- Citações
- 11
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China
Yanhua Song, Wei Shu, Yi Pei, Juan Du, Guihui Wu, Hua Wang, Fengling Mi, Fangchao Liu, Liping Ma, Li Xie et al.
Descritores MeSH
- Linezolid
- Antitubercular Agents
- Clofazimine
- Cycloserine
- Rifampin
- Tuberculosis, Multidrug-Resistant
- Diarylquinolines
- Levofloxacin
- Female
- Humans
Veja também
Estudos relacionados
- Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)
- A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
- Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment
- Executive Summary: Clinical Practice Guidelines on the Management of Resistant Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)